The Actos bladder cancer litigation resulted in a landmark $2.4 billion settlement in 2015, with Takeda Pharmaceuticals agreeing to resolve approximately 9,000 lawsuits from patients who developed bladder cancer after taking the diabetes medication. The average payout was close to $300,000 per victim, though individual amounts varied based on factors like cancer severity, duration of Actos use, and documented medical expenses. Ninety-seven percent of claimants accepted the settlement offer, and the multidistrict litigation officially closed in April 2018. However, the Actos legal saga is far from over.
A new RICO class action lawsuit””the first of its kind certified against a major pharmaceutical company””is proceeding through the courts with a trial expected in 2026. This case targets third-party payers like insurance companies and health funds that covered Actos prescriptions between 1999 and 2010, with legal experts estimating potential damages exceeding $7 billion. For individuals who previously suffered bladder cancer from Actos but did not participate in the original settlement, options are now extremely limited, as no law firms are currently accepting new individual cases. This article covers the details of the original settlement, the bellwether trial that preceded it, the ongoing RICO litigation, and what these developments mean for different parties affected by Actos.
Table of Contents
- What Were the Terms of the 2015 Actos Bladder Cancer Settlement?
- How Did the $9 Billion Jury Verdict Shape Settlement Negotiations?
- What Is the RICO Class Action Against Takeda and Eli Lilly?
- Who Can Participate in Current Actos Litigation?
- What Damages Could the RICO Case Produce?
- How Does This Compare to Other Pharmaceutical Settlements?
- What Happens Next in the Actos RICO Case?
- Conclusion
What Were the Terms of the 2015 Actos Bladder Cancer Settlement?
takeda Pharmaceuticals reached the $2.4 billion settlement agreement in 2015 after years of mounting litigation pressure. The settlement covered more than 8,000 individual claims consolidated in multidistrict litigation, making it one of the largest pharmaceutical settlements in U.S. history at the time. Importantly, Takeda did not admit any guilt or wrongdoing as part of the agreement and continued to maintain that Actos was both safe and effective when used as directed.
The settlement structure meant that not all claimants received identical payouts. Compensation was distributed based on a points system that weighed factors including the severity of the cancer diagnosis, length of time the plaintiff used Actos, strength of medical documentation linking the drug to the illness, and other case-specific circumstances. Some claimants with particularly severe cases or strong evidence received significantly more than the $300,000 average, while others with less documented harm received less. For context, the settlement came after Takeda had already faced devastating jury verdicts. Settling allowed the company to cap its liability and avoid the unpredictable outcomes of thousands of individual trials””a calculated business decision rather than an admission of responsibility.
How Did the $9 Billion Jury Verdict Shape Settlement Negotiations?
Before the 2015 settlement, a bellwether trial in April 2014 sent shockwaves through the litigation. A Louisiana jury awarded Terrence Allen, a former shopkeeper from New York who developed bladder cancer after taking Actos, $9 billion in punitive damages plus $1.5 million in compensatory damages. This remains one of the largest pharmaceutical jury verdicts ever recorded, though it was ultimately reduced to $36.8 million on appeal. The Allen verdict demonstrated the potential jury hostility Takeda faced and likely accelerated settlement negotiations.
Bellwether trials serve as test cases in mass tort litigation, helping both sides gauge how juries respond to the evidence and arguments. When a jury returns a $9 billion verdict””even if later reduced””it signals significant risk for the defendant company. However, it’s important to understand that bellwether verdicts don’t guarantee similar outcomes for all plaintiffs. Some cases have stronger evidence than others, and individual circumstances vary widely. The Allen case represented what could happen under favorable conditions for the plaintiff, but many cases had weaker documentation or more complicated causation questions.
What Is the RICO Class Action Against Takeda and Eli Lilly?
The current Actos litigation involves an entirely different legal theory and set of plaintiffs. In June 2025, the Ninth Circuit Court of Appeals affirmed class certification in *Painters & Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Company Limited*. This case represents the first non-settlement national RICO class action ever certified against a major pharmaceutical company””a significant legal milestone.
The RICO lawsuit alleges that Takeda and Eli Lilly (which co-marketed Actos) engaged in a pattern of racketeering activity by concealing evidence that Actos causes bladder cancer. According to the complaint, the companies knew about the cancer risk but suppressed this information to protect their profits. The class consists of third-party payers””health insurance companies, union health funds, government healthcare programs, and similar entities””that paid for Actos prescriptions between July 1, 1999 and September 17, 2010. This case does not benefit individual patients who took Actos. Instead, it seeks to recover the money that insurers and health funds spent on a drug they claim they would not have covered, or would have covered at lower rates, had the cancer risk been properly disclosed.
Who Can Participate in Current Actos Litigation?
For individuals who took Actos and developed bladder cancer, the window for legal action has effectively closed. No law firms are currently accepting new individual bladder cancer cases related to Actos. The statute of limitations in most states has long since expired for anyone who developed cancer years ago, and the 2015 settlement resolved the vast majority of pending claims. The RICO class action operates differently. Third-party payers that reimbursed Actos prescriptions during the class period may automatically be included in the class depending on how the court defines class membership.
These entities don’t need to take affirmative action to join””they’re part of the class unless they opt out. However, this litigation benefits institutional payers, not individual patients or their families. For patients who developed bladder cancer after using Actos but never filed a claim, the unfortunate reality is that legal remedies are no longer available in most circumstances. Those who participated in the 2015 settlement and accepted payments signed releases that prevent future claims. The settlement achieved finality for Takeda regarding individual injury claims, which was one of the company’s primary objectives.
What Damages Could the RICO Case Produce?
Legal experts estimate that total damages in the RICO class action could exceed $7 billion, making it potentially even larger than the 2015 individual settlement. Under RICO, successful plaintiffs can recover treble damages””three times their actual losses””plus attorney fees. This multiplier effect explains how damages could reach such substantial figures. The calculation of actual damages involves determining how much third-party payers spent on Actos prescriptions during the class period and what portion of that spending was attributable to the alleged fraud. If insurers would have imposed restrictions on Actos coverage, required prior authorizations, or excluded the drug from formularies had they known about the cancer risk, they can argue they overpaid by continuing to cover it at favorable rates.
However, Takeda and Eli Lilly have not conceded defeat. The companies have asked the U.S. Supreme Court to review the Ninth Circuit’s decision affirming class certification. If the Supreme Court agrees to hear the case and reverses class certification, the litigation could collapse or be forced to proceed on a much smaller scale. Plaintiffs face the risk that their class could be decertified at any point before or during trial.
How Does This Compare to Other Pharmaceutical Settlements?
The $2.4 billion Actos settlement ranks among the largest pharmaceutical mass tort resolutions, though it falls short of some record-breaking cases. The Vioxx settlement reached $4.85 billion in 2007, and various opioid-related settlements have exceeded $10 billion in aggregate. The Actos resolution sits comfortably in the upper tier of significant pharmaceutical liability cases.
What distinguishes the ongoing RICO litigation is its legal novelty. RICO claims against pharmaceutical companies typically settle before class certification, making this the first such case to achieve certified class status at the national level. A plaintiff victory at trial could establish precedent encouraging similar claims against other drug manufacturers accused of concealing safety information.
What Happens Next in the Actos RICO Case?
Trial in the RICO class action is expected in 2026, though the precise timeline depends on whether the Supreme Court agrees to review the case. If the high court declines to hear the appeal or upholds the class certification, the case will proceed toward trial in the Ninth Circuit. A Supreme Court reversal, on the other hand, could significantly delay or derail the litigation.
Settlement remains possible at any stage. Pharmaceutical companies often prefer negotiated resolutions over the uncertainty of jury verdicts, and Takeda has previously demonstrated willingness to settle Actos claims. However, the RICO case presents different dynamics than the individual injury lawsuits””the institutional plaintiffs may be less motivated to accept discounted settlements, and the potential treble damages create different settlement math for both sides.
Conclusion
The Actos bladder cancer litigation represents one of the most significant pharmaceutical liability cases of the past decade. The 2015 settlement provided compensation averaging $300,000 to thousands of cancer victims, while the ongoing RICO case could add billions more in liability for Takeda and Eli Lilly. These cases illustrate how pharmaceutical litigation can evolve from individual injury claims into broader fraud allegations over time.
For individuals affected by Actos, the settlement window has closed, and no firms are currently accepting new cases. The RICO litigation benefits third-party payers rather than patients. Those who participated in the original settlement received their compensation years ago, and the legal system has moved on to addressing different aspects of the alleged wrongdoing.